OC-0546: Minimally ablative dose (MAD) for the treatment of lung cancer using SBRT: Is it such a “MAD” concept?  by Chetty, I.J. et al.
2nd ESTRO Forum 2013  S209 
	
OC-0546   
Minimally ablative dose (MAD) for the treatment of lung cancer 
using SBRT: Is it such a “MAD” concept? 
I.J. Chetty1, S. Devpura1, D. Chen1, D. Liu1, S. Kumar1, N. Wen1, C. 
Fraser1, M.S. Siddiqui1, M. Ajlouni1, B. Movsas1 
1Henry Ford Health System, Radiation Oncology, Detroit, USA  
 
Purpose/Objective: To determine whether individualization of dose 
prescriptions based on tumor size and location is a feasible approach 
for SBRT-based treatment of non-small cell lung cancer. 
Materials and Methods: Treatment plans for 133 NSCLC patients 
treated using 12 Gy/Fxn x 4, and planned using a pencil-beam (1D-
equivalent-path-length, EPL-1D) algorithm were retrospectively 
calculated with a Monte Carlo (MC)-based algorithm using EPL-1D plan 
parameters. 4D imaging was performed to generate an ITV. PTV 
margin was 5 mm. For each plan, generalized equivalent dose (gEUD) 
and tumor control probability (TCP with SF=0.28) were computed. 
Tumors were stratified according to peripheral ('island', N=39), lung-
wall (attached to the rib-cage, N=44) and central locations (N=50), as 
well as tumor size and mean plan field size.  
Results: GEUD values for the EPL-1D algorithm were based on 
prescription doses and ranged from 48-49 Gy for all cases. MC-
computed gEUD decreased significantly with decreasing tumor size; 
values in Gy were 41.9+3.6 for average plan field widths (FW) 
between 3-5 cm; 43.8+3.2 (5>FW>7 cm); 45.9+3.3 between (7>FW>10 
cm). TCP’s for the EPL-1D algorithm increased with decreasing tumor 
size with values of 0.88+0.04 (3>FW>5 cm); 0.85+0.03 (5>FW>7 cm); 
0.80+0.05 (7>FW>10 cm). On the other hand, MC-computed TCP’s 
remained relatively constant as a function of tumor size; values were 
0.77+0.07 (3>FW>5 cm); 0.76+0.05 (5>FW>7 cm); 0.76+0.05 (7>FW>10 
cm). Results were consistent for 'island', lung wall and central tumors. 
There was no correlation between tumor size and local control rate 
among the 92% of patients who were controlled locally at 2-years, 
which is consistent with the MC-calculated TCPs. Note, however, that 
MC-computed gEUDs were significantly lower for smaller tumor sizes. 
This suggests that although smaller tumors were receiving much lower 
doses (on average, 10.5 Gy vs. 12 Gy per fxn), they were being 
controlled. These findings are consistent with radiobiology; smaller 
tumors have fewer tumor cells and therefore require lower doses to 
be controlled relative to larger tumors. Results are also suggestive 
that dose could be tailored according to size and location of the 
tumor, i.e. one size does not need to fit all. We speculate as well that 
the concept of minimally ablative dose (MAD) is perhaps not an 
unreasonable approach to consider for smaller tumors. Dose de-
escalation for smaller tumors, based on the mimimum ablative dose is 
likely to be clinically relevant for tumors situated close to normal 
organs (e.g. ribs, centrally located airways) and for patients being 
treated for recurrent disease.  
  
PTV 
Volume  
(cm3) 
Avg. 
Field  
(cm) 
EPL-
1D_gEUD 
(Gy) 
EPL-1D_TCP 
(SF=0.28) 
MC_gEUD 
(Gy) 
MC_TCP 
(SF=0.28) 
Lung-
island N=39
27.6 ± 
29.5 
5.0 ±
1.0 48.7 ± 2.4 0.87 ± 0.04 41.3 ± 3.3 0.74 ± 0.06 
Lung-
wall N=44
53.4 ± 
59.8 
5.9 ±
1.5 49.1 ± 1.7 0.85 ± 0.04 44.7 ± 3.2 0.78 ± 0.05 
Lung-
central N=50
45.6 ± 
41.6 
5.8 ±
1.4 48.6 ± 2.5 0.84 ± 0.05 43.9 ± 3.5 0.77 ± 0.06 
  
Conclusions: Retrospective dose analysis of 133 NSCLC patients 
treated with SBRT is suggestive that individualization of doses based 
on tumor size and location may be a feasible approach toward 
achieving equivalent local control and possibly reducing toxicity based 
on the clinical circumstances.  
   
OC-0547   
How to identify patient specific rectal sub-region likely responsible 
of rectal bleeding in prostatic IMRT? 
G. Dréan1, O. Acosta1, J.D. Arango1, A. Simon1, G. Cazoulat1, J. Zhu1, 
P. Haigron1, R. de Crevoisier2 
1INSERM U1099, Université de Rennes 1 - Laboratoire du Traitement 
du Signal et de l'Image, Rennes, France  
2Centre Eugène Marquis, Département de Radiothérapie, Rennes, 
France  
 
Purpose/Objective: Current toxicity models in prostate cancer 
radiotherapy, based on dose-volume histograms, do not enable to 
identify region in the rectum involved in bleeding. Localize such 
regions may be crucial in IMRT to decrease rectal toxicity. The goals 
of this study were: 
- firstly to assess the rectal bleeding/local dose correlation using 
voxel wise statistics on several anatomically different templates (thus 
avoiding a specific template effect), 
- secondly to back propagate the significant regions found on these 
templates to a specific patient (pts). 
Materials and Methods: A total of 93 patients receiving a total dose of 
80Gy in the prostate by IMRT were included in the analysis. Rectal 
bleeding (RB) at two years was analyzed (> grade 1). The series was 
divided in 2 cohorts: one for training (63 pts) and the other one for 
testing (30 pts).  A total of 63 randomly chosen individuals (12/51 
with/without RB) 3D CT scans and planned dose were non-rigidly 
registered towards 10 templates in a 3 step process: one rigid 
registration and two elastic registrations (demons algorithm). The 
registrations were designed to ensure accurate alignments of rectums 
and dose distributions. Dice scores and Dose-Organs Overlap (DOO) 
were computed on the rectum for each pt on the 10 templates to 
assess the accuracy of the registration. 
Two-sampled t-tests were then performed on each template at a 
voxel-basis leading to the computation of 3D maps for both, the dose 
differences (and the p-values) between the mean dose of pts having 
or not toxicity. Significant regions (p<0.01) were then characterized in 
terms of absolute volume, mean dose difference and localization in 
the rectum. The last one was defined as the distance of the significant 
region to the prostate and the seminal vesicles surfaces. 
The 10 significant regions from each template were then back 
propagated, using the same registration method, on 30 'test patients' 
(6/24 with/without RB) leading to the computation of a probability 
map of the significant region on the rectum for each test patient. The 
significant regions for toxicity were then delineated using a majority 
vote approach. 
Results:  
Median follow-up was 31 months (6 to 64). Two year RB rate were 
20%(95% CI: 12-27). 
1. Median Dice and DOO were 0.98 (sd 0.01) and 0.97 (sd 0.02).  
2. Significant differences of dose related with toxicity were found 
in large regions on the 10 templates, corresponding to 5.95% of 
the rectal volume (in average). The anterior wall of the rectum 
appears involved in RB on the 10 templates (fig): 92.17% (sd 6.3) 
of the volume of the significant region were localized within the 
first 15mm of the rectum close to the prostate. In these regions, 
pts with RB received 6.7Gy (sd 1.3) more than pts without RB. 
Conclusions: The anterior wall of the rectum appears strongly 
involved in RB. Our templates constitute a library of RB correlated 
region, which can be used to more precisely identify the region at risk 
of rectal bleeding for a given patient. This new approach opens the 
way for patient specific treatment by enabling to add IMRT constraints 
on region likely responsible of RB. 
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